Learn about the new drug approved for multiple sclerosis.
“We’ve been banging on a wall with a bunch of drugs, and we finally put a big crack in the wall,” said Dr. Jerry Wolinsky, professor emeritus at the University of Texas in Houston. Wolinsky was a lead author on a study in January showing that the drug, ocrelizumab, slowed the decline in patients with primary progressive multiple sclerosis.
Multiple sclerosis is a neurological disease that affects hundreds of thousands of people, mostly women, in the United States. The disease scars nerve tissue and causes a range of symptoms, from vision problems to paralysis. While the most common form of the disease gets better and worse over time, about 10% to 15% of patients have a form known as primary progressive, which gets slowly worse over time. There had been no approved drugs for this variation until now.
“The drug is so much more effective at shutting down inflammation,” said Dr. David Hafler, a multiple sclerosis researcher and the chair of neurology at Yale School of Medicine.
Read full article: Multiple sclerosis: New treatment gets FDA approval – CNN.com